Posted by Michael Wonder on 18 May 2018
EMA review of Zinbryta confirms medicine’s risks outweigh its benefits
18 May 2018 - Multiple sclerosis medicine no longer authorised and has been recalled from hospitals and pharmacies
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that the multiple sclerosis medicine Zinbryta (daclizumab beta) poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs.
Patients could be at risk from the start of treatment and for several months after stopping treatment, and it is not possible to predict which patients will be affected. The PRAC therefore confirmed its previous conclusions that risks of Zinbryta outweigh its benefits for patients with multiple sclerosis.
